Covid-19 in transplant recipients: the spanish experience.

Coll, Elisabeth; Fernández-Ruiz, Mario; Sánchez-Álvarez, J Emilio; Martínez-Fernández, José Ramón; Crespo, Marta; Gayoso, Jorge; Bada-Bosch, Teresa; Oppenheimer, Federico; Moreso, Francesc; López-Oliva, María O; Melilli, Edoardo; Rodríguez-Ferrero, Mª Luisa; Burgos, Elena; Facundo, Carme; Lorenzo, Inmaculada; Yañez, Íñigo; Galeano, Cristina; Roca, Ana; Cabello, Mercedes; Gómez-Bueno, Manuel; Graus, Javier; Lladó, Laura; de Pablo, Alicia; Loinaz, Carmelo; Aguado, Beatriz; Hernández, Domingo; Domínguez-Gil, Beatriz

We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).